Advanced Proteome Therapeutics Corporation (V:APC)

Business Focus: Shell Companies

Get the company report for the most recent outlook updated daily

Dec 05, 2023 06:50 am ET

Canadian Investment Regulatory Organization Trading Halt - APC.H

VANCOUVER, BC, Dec. 5, 2023 /CNW/ - The following issues have been halted by CIRO

Mar 06, 2023 06:47 pm ET

Advanced Proteome Therapeutics to Proceed with Its Proposed Plan of Arrangement

Burnaby, British Columbia--(Newsfile Corp. - March 6, 2023) - Advanced Proteome Therapeutics Corporation (TSXV: APC) (FSE: 0E81) ("APC" or the "Company") is pleased to announce that all conditions have been satisfied or waived and the Board of Directors of the Company has authorized the Company to complete its plan of arrangement under the Business Corporations Act (British Columbia) (the "Arrangement") as set forth in the Company's Management Information Circular dated January 17, 2023 and approved by shareholders at the Company's annual, general and special shareholder meeting ("AGSM") held on February 22, 2023 and by the Supreme Court of British Columbia pursuant its final order dated February 27, 2023..

Jan 17, 2023 02:39 pm ET

Advanced Proteome Therapeutics Announces Its Proposed Plan of Arrangement

Burnaby, British Columbia--(Newsfile Corp. - January 17, 2023) - Advanced Proteome Therapeutics Corporation (TSXV: APC) (FSE: 0E81) ("APC" or the "Company") is pleased to announce that the Supreme Court of British Columbia (the "Court") has issued an interim order (the "Interim Order") on January 16, 2023 in connection with the Company's proposed Plan of Arrangement (see below). The Interim Order, among other things, authorizes the holding of an annual and special meeting (the "Meeting") of the holders of common shares of the Company (the "APTC Shareholders") to consider and vote upon the Plan of Arrangement under the Business Corporations Act (British Columbia).

Jan 17, 2023 01:50 pm ET

IIROC Trading Resumption - APC

VANCOUVER, BC, Jan. 17, 2023 /CNW/ - Trading resumes in:

Jan 17, 2023 01:32 pm ET

IIROC Trading Halt - APC

VANCOUVER, BC, Jan. 17, 2023 /CNW/ - The following issues have been halted by IIROC:

Dec 23, 2022 05:08 pm ET

Advanced Proteome Therapeutics Announces Closing of Non-Brokered Private Placement

Burnaby, British Columbia--(Newsfile Corp. - December 23, 2022) - Advanced Proteome Therapeutics Corporation (TSXV: APC) (FSE: 0E81) ("APC" or the "Company") is pleased to announce that, subject to the approval of the TSX Venture Exchange, it has closed a non-brokered private placement (the "Private Placement" or the "Offering") raising gross proceeds of $72,500.00 by the issuance of 1,450,000 shares at a price of $0.05 per share.

Nov 21, 2022 07:40 pm ET

Advanced Proteome Therapeutics Announces Appointment of Mr. Cory Brandolini to the Board of Directors

Vancouver, British Columbia--(Newsfile Corp. - November 21, 2022) - Advanced Proteome Therapeutics Corporation (TSXV: APC) (FSE: 0E8) ("APC" or the "Company") is pleased to announce that it has appointed Mr. Cory Brandolini to the board of directors.

Aug 17, 2022 08:30 am ET

Advanced Proteome Therapeutics Manuscript Published in Bioconjugate Chemistry

Vancouver, British Columbia--(Newsfile Corp. - August 17, 2022) - Advanced Proteome Therapeutics Corporation (TSXV: APC) (FSE: 0E81) ("APC" or the "Company"), is pleased to announce that its US subsidiary, Advanced Proteome Therapeutics Inc. ("APTI"), has had its technology featured in a peer-reviewed publication.

Aug 03, 2022 01:45 pm ET

Advanced Proteome Therapeutics Receives Issued Patent

Vancouver, British Columbia--(Newsfile Corp. - August 3, 2022) - Advanced Proteome Therapeutics Corporation (TSXV: APC) (FSE: 0E81) ("APC" or the "Company") is pleased to announce that the United States Patent and Trademark Office has issued a patent to its US subsidiary, Advanced Proteome Therapeutics Inc. ("APTI").

Apr 13, 2022 10:28 am ET

Advanced Proteome Therapeutics Receives Notice of Allowance for Patent Claims

Vancouver, British Columbia--(Newsfile Corp. - April 13, 2022) - Advanced Proteome Therapeutics Corporation (TSXV: APC) (FSE: 0E8) ("APC" or the "Company") is pleased to announce that its US subsidiary, Advanced Proteome Therapeutics Inc. ("APTI") has received a notice of allowance for patent claims covering key intellectual property.

Mar 18, 2022 03:46 pm ET

Advanced Proteome Therapeutics Announces Warrant Extension

Vancouver, British Columbia--(Newsfile Corp. - March 18, 2022) - Advanced Proteome Therapeutics Corporation (TSXV: APC) (FSE: 0E81) ("APC" or the "Company") announces that, it has applied to the TSX Venture Exchange for approval to amend the expiration of certain outstanding warrants (the "Warrants"). The Warrants' exercise price and original expiry date are detailed below. The Warrants expiry date is to be extended to September 30, 2022. The warrants to be amended do not include any warrants issued to finders or agents. No other terms of the warrants are to be amended and the exercise remains at $0.27.

Feb 03, 2022 02:50 pm ET

Advanced Proteome Therapeutics Update on Plans for 2022

Vancouver, British Columbia--(Newsfile Corp. - February 3, 2022) - Advanced Proteome Therapeutics Corporation (TSXV: APC) (FSE: 0E81) ("APC" or the "Company"), is pleased to announce that its US subsidiary, Advanced Proteome Therapeutics Inc. ("APTI") is providing an update on plans for the upcoming year.

Nov 23, 2021 10:48 am ET

Advanced Proteome Therapeutics Expands Operations

Vancouver, British Columbia--(Newsfile Corp. - November 23, 2021) - Advanced Proteome Therapeutics Corporation (TSXV: APC) (FSE: 0E81) ("APC" or the "Company"), is pleased to announce that its US subsidiary, Advanced Proteome Therapeutics Inc. ("APTI") is expanding operations with a new hire and additional lab space.

Oct 04, 2021 11:14 am ET

Advanced Proteome Therapeutics Technology Featured in Oral Presentation at the World Molecular Imaging Congress

Vancouver, British Columbia--(Newsfile Corp. - October 4, 2021) - Advanced Proteome Therapeutics Corporation (TSXV: APC) (FSE: 0E8) ("APC" or the "Company"), is pleased to announce that its US subsidiary, Advanced Proteome Therapeutics Inc. ("APTI") will have its technology featured in an oral presentation at the World Molecular Imaging Congress.

Aug 24, 2021 09:45 am ET

Advanced Proteome Therapeutics Provides Update on COVID Program

Burnaby, British Columbia--(Newsfile Corp. - August 24, 2021) - Advanced Proteome Therapeutics Corporation (TSXV: APC) (FSE: 0E8) ("APC" or the "Company"), reports that its US subsidiary, Advanced Proteome Therapeutics Inc. ("APTI"), is dedicating additional resources to its SARS-CoV-2 protease inhibitor program.

Jul 21, 2021 08:30 am ET

Advanced Proteome Therapeutics Announces Appointment of Dr. Benjamin Krantz to CEO

Burnaby, British Columbia--(Newsfile Corp. - July 21, 2021) - Advanced Proteome Therapeutics Corporation (TSXV: APC) (FSE: 0E8) ("APC" or the "Company") is pleased to announce that as previously planned, Dr. Benjamin Krantz has taken over the role of CEO at its US subsidiary, Advanced Proteome Therapeutics Inc. ("APTI").

Jun 09, 2021 01:40 pm ET

Advanced Proteome Therapeutics Announces Renowned Scientist to Join Scientific Advisory Board and New Chemistry Hire

Vancouver, British Columbia--(Newsfile Corp. - June 9, 2021) - Advanced Proteome Therapeutics Corporation (TSXV: APC) (FSE: 0E8) ("APC" or the "Company") reports that its US subsidiary, Advanced Proteome Therapeutics Inc. ("APTI") has a appointed a new Scientific Advisory Board Member and hired a new lead chemist.

Apr 13, 2021 05:12 pm ET

Advanced Proteome Therapeutics Announces Closing Final Tranche of Non-Brokered Private Placement

Burnaby, British Columbia--(Newsfile Corp. - April 13, 2021) - Advanced Proteome Therapeutics Corporation (TSXV: APC) (FSE: 0E81) ("APC" or the "Company") is pleased to announce that, further to its news release of March 11, 2021 and subject to the approval of the TSX Venture Exchange, it has closed the final tranche of its non-brokered private placement (the "Private Placement") raising gross proceeds of $524,610 by the issuance of 2,559,073 units at a price of $0.205 per unit.

Mar 11, 2021 01:38 pm ET

Advanced Proteome Therapeutics Announces Increase of Non-Brokered Private Placement

Vancouver, British Columbia--(Newsfile Corp. - March 11, 2021) - Advanced Proteome Therapeutics Corporation (TSXV: APC) (FSE: 0E8) ("APC" or the "Company") is pleased to announce that it has increased its previously announced private placement financing (see March 1st, 2021 news release) from up to 6,097,561 units of the Company ("units) to up to 7,317,073 Units at a price of $0.205 per unit for gross proceeds of up to $1,500,000. Each unit will consist of one common share and one transferable common share purchase warrant of the Company, with each whole warrant exercisable for a period of 12 months from the date of closing at a price of $0.27 per share.

Mar 01, 2021 01:11 pm ET

Advanced Proteome Therapeutics Announces a Non-Brokered Private Placement

Vancouver, British Columbia--(Newsfile Corp. - March 1, 2021) - Advanced Proteome Therapeutics Corporation (TSXV: APC) (FSE: 0E8) ("APC" or the "Company") announces that, subject to the approval of the TSX Venture Exchange (the "Exchange"), it proposes to raise up to $1,250,000 through a non-brokered private placement of up to 6,097,561 units at a price of $0.205 per unit. Each unit will consist of one common share and one transferable common share purchase warrant of the Company, with each whole warrant exercisable for a period of 12 months from the date of closing at a price of $0.27 per share.

Dec 17, 2020 01:03 pm ET

IIROC Trading Resumption - APC

VANCOUVER, BC, Dec. 17, 2020 /CNW/ - Trading resumes in:

Dec 17, 2020 01:02 pm ET

Advanced Proteome Therapeutics Announces Dr. Benjamin Krantz to Join Company as CEO

Burnaby, British Columbia--(Newsfile Corp. - December 17, 2020) - Advanced Proteome Therapeutics Corporation (TSXV: APC) (FSE: 0E8) ("APC" or the "Company'), is pleased to announce that Dr. Benjamin Krantz will be joining the Company's US subsidiary Advanced Proteome Therapeutics Inc. ("APTI") as CEO following the completion of his oncology fellowship at NYU Langone Health on July 1st, 2021. Bill Dickie will continue his role as interim CEO of APTI until then and remain a member of the board of directors after.

Dec 17, 2020 12:10 pm ET

IIROC Trading Halt - APC

VANCOUVER, BC, Dec. 17, 2020 /CNW/ - The following issues have been halted by IIROC:

Aug 14, 2020 10:45 am ET

Advanced Proteome Therapeutics Provides Project Update

Vancouver, British Columbia--(Newsfile Corp. - August 14, 2020) - Advanced Proteome Therapeutics Corporation (TSXV: APC) (FSE: 0E8) ("APC" or the "Company"), is pleased to announce that its US subsidiary, Advanced Proteome Therapeutics Inc. ("APTI"), is rapidly advancing three projects with the potential to add significant shareholder value.

Jul 09, 2020 04:20 pm ET

IIROC Trading Resumption - APC

VANCOUVER, BC, July 9, 2020 /CNW/ - Trading resumes in:

Jul 09, 2020 03:23 pm ET

Advanced Proteome Therapeutics Files Provisional IP for Compounds Targeting SARS-CoV-2

Burnaby, British Columbia--(Newsfile Corp. - July 9, 2020) - Advanced Proteome Therapeutics Corporation (TSXV: APC) (FSE: 0E8) ("APC" or the "Company"), is pleased to announce that its US subsidiary, Advanced Proteome Therapeutics Inc. ("APTI"), has filed for patent protection on a family of therapeutic candidates against SARS-CoV-2, the virus which causes COVID-19 and has initiated a project to rapidly manufacture test quantities of these drugs.

Jul 09, 2020 02:24 pm ET

IIROC Trading Halt - APC

VANCOUVER, BC, July 9, 2020 /CNW/ - The following issues have been halted by IIROC:

Nov 14, 2018 08:30 am ET

Advanced Proteome Therapeutics Reports Positive Results and Advances Collaboration with Heidelberg Pharma

Advanced Proteome Therapeutics Corporation (“APC” or the “Company”) (TSXV: APC) (FSE: 0E8), is pleased to announce very positive results from animal studies in collaboration with Heidelberg Pharma. Antibody–drug conjugates (ADCs) are an emerging...

Oct 15, 2018 08:30 am ET

Advanced Proteome Therapeutics Reports Progress on Collaboration with Noria Pharmaceuticals

Advanced Proteome Therapeutics Corporation (“APC” or the “Company”) (TSXV: APC) (FSE: 0E8), is pleased to announce the successful completion of the first phase of the Collaboration of APC with Noria Pharmaceuticals Inc. in the rapidly growing and...

Oct 09, 2018 09:00 am ET

APC Comments on Favorable Results in Initial Animal Studies

Advanced Proteome Therapeutics Corporation (“APC” or the “Company”) (TSXV: APC) (FSE: 0E8), is pleased to report favorable results in initial animal studies. Antibody–drug conjugates (ADCs) are an emerging class of therapeutic agents with the...

Sep 13, 2018 08:30 am ET

Advanced Proteome Therapeutics Announces Progress on Antibody-Radioisotope Conjugate Initiative

Advanced Proteome Therapeutics Corporation (“APC” or the “Company”) (TSXV: APC) (FSE: 0E8), is pleased to report significant progress in applying the Company’s site-selective linker technology to advance the rapidly growing field of...

Sep 11, 2018 08:30 am ET

Advanced Proteome Therapeutics Provides Overview of Current Activities and Strategic Objectives

Advanced Proteome Therapeutics Corporation (“APC” or the “Company”) (TSXV: APC) (FSE: 0E8), is pleased to provide an overview of current projects prior to more detailed news releases that will be disclosed shortly. Radioimmunoconjugates APC’s...

Aug 23, 2018 05:30 pm ET

Advanced Proteome Therapeutics Announces Closing of First Tranche of a Non-Brokered Private Placement

Advanced Proteome Therapeutics Corporation (“APC” or the “Company”) (TSXV: APC) (FSE: 0E8) is pleased to announce that it has closed a first tranche of a non-brokered private placement (the “Private Placement”) raising gross proceeds of $302,000...

Aug 03, 2018 04:00 pm ET

Advanced Proteome Therapeutics Announces Non-Brokered Private Placement

Advanced Proteome Therapeutics Corporation (“APC” or the “Company”) (TSXV: APC) (FSE: 0E8) is pleased to announce that, subject to the approval of the TSX Venture Exchange (the “Exchange”), it proposes to raise up to $400,000 through a...

Jul 17, 2018 09:03 am ET

Advanced Proteome Therapeutics Announces Collaboration with Noria Pharmaceuticals

Advanced Proteome Therapeutics Corporation (“APC” or the “Company”) (TSXV:APC) (FSE:0E8), is pleased to announce the collaboration of APC with Noria Pharmaceuticals Inc. in the rapidly growing field of antibody radioisotope conjugates. APC will...

Jun 18, 2018 08:30 am ET

Advanced Proteome Therapeutics Advances its Technological Capability

Advanced Proteome Therapeutics Corporation (“APC” or the “Company”) (TSXV:APC) (FSE:0E8), is pleased to report continuing progress on its efforts to develop superior antibody drug conjugates (ADCs). Proceeding from cytotoxicity studies to the...

Jun 06, 2018 05:05 pm ET

Advanced Proteome Therapeutics Announces Appointment of Bill Dickie as Chief Executive Officer, President and Director

Advanced Proteome Therapeutics Corporation (“APC” or the “Company”) (TSXV:APC) (FSE:0E8) is pleased to announce the appointment of Mr. Bill Dickie as Chief Executive Officer, President and Director of the company, effective June 6, 2018. Mr. Dickie...

May 01, 2018 08:30 am ET

Advanced Proteome Therapeutics Updates its Activities During the 3rd Quarter, FY 2018

Advanced Proteome Therapeutics Corporation (“APC” or the “Company”) (TSXV:APC) (FSE:0E8) is pleased to provide an update of progress during the third quarter, FY 2018. The Company, in its pursuit of commercial success is vigourously applying...

Apr 24, 2018 08:30 am ET

Advanced Proteome Therapeutics Announces Appointment of Scientific Advisory Board Members

VANCOUVER, British Columbia, April 24, 2018 (GLOBE NEWSWIRE) -- Advanced Proteome Therapeutics Corporation (“APC” or the “Company”) (TSXV:APC) (FSE:0E8) is pleased to announce the appointments of two new members to its Scientific Advisory Board (SAB): Dr. Aditya Bardia, a...

Apr 17, 2018 08:28 am ET

IIROC Trading Resumption - APC

VANCOUVER, April 17, 2018 /CNW/ - Trading resumes in:

Apr 16, 2018 05:04 pm ET

Advanced Proteome Therapeutics Announces Appointment of New Board Members

VANCOUVER, British Columbia, April 16, 2018 (GLOBE NEWSWIRE) -- Advanced Proteome Therapeutics Corporation (“APC” or the “Company”) (TSXV:APC) (FSE:0E8) is pleased to announce the appointments of Dr. John R. Garrett and Paul Woodward to its Board of Directors.

Apr 16, 2018 11:11 am ET

IIROC Trading Halt - APC

VANCOUVER, April 16, 2018 /CNW/ - The following issues have been halted by IIROC:

Apr 16, 2018 08:00 am ET

Advanced Proteome Therapeutics Announces CEO and Director Resignations

VANCOUVER, British Columbia, April 16, 2018 (GLOBE NEWSWIRE) -- Advanced Proteome Therapeutics Corporation (“APC” or the “Company”) (TSX-V:APC) (FSE:0E8) announces that its Board of Directors has accepted the resignation of Mr. Randal Chase as President, Chief Executive Officer...

Feb 07, 2018 08:30 am ET

Advanced Proteome Therapeutics and ImmunoBiochem Corporation enter into a Collaboration and Option Agreement

VANCOUVER, British Columbia and TORONTO, Feb. 07, 2018 (GLOBE NEWSWIRE) -- Advanced Proteome Therapeutics Corporation (APC), a therapeutics discovery and development company, and ImmunoBiochem Corporation, today announced entering into a Collaboration and Option agreement to develop superior antibody-drug...

Feb 05, 2018 08:00 am ET

Advanced Proteome Therapeutics Announces New Patent Grant

Advanced Proteome Therapeutics Corporation ("APC" or the "Company") (TSX VENTURE: APC) (FRANKFURT: 0E8) is pleased to announce that the Japanese Patent Office has decided to grant a patent for APC's Japanese Patent Application No. :2015-511804,...

Jan 31, 2018 08:00 am ET

Advanced Proteome Therapeutics Announces Anti-Cancer R&D Gathers Momentum

Advanced Proteome Therapeutics Corporation ("APC" or the "Company") (TSX VENTURE: APC) (FRANKFURT: 0E8) announces that during the 2017 calendar year, it has witnessed very significant progress in APC's scientific program that has bolstered...

Jan 08, 2018 08:30 am ET

Advanced Proteome Therapeutics and Heidelberg Pharma Progress Collaborative Program

Advanced Proteome Therapeutics Corporation (APC), a therapeutics discovery and development company, and Heidelberg Pharma announced today advances in their collaborative activities. The companies have agreed to test the combination of APC's...

Nov 20, 2017 08:00 am ET

Advanced Proteome Therapeutics Expands Antibody-Drug Conjugate Collaboration

Advanced Proteome Therapeutics Corporation ("APC" or the "Company") (TSX VENTURE: APC) (FRANKFURT: 0E8) a biotechnology company focused on developing superior targeted protein therapeutics, is expanding the collaboration with the National Research...

Nov 15, 2017 08:00 am ET

Advanced Proteome Therapeutics Announces Formation of Business Advisory Committee

Advanced Proteome Therapeutics Corporation ("APC" or the "Company") (TSX VENTURE: APC) (FRANKFURT: 0E8), announced today that it has formed an Advisory Business Committee to assist in implementing the Company's current plans and identifying means to...

Nov 06, 2017 08:30 am ET

Advanced Proteome Therapeutics to Attend 2017 BIO-Europe Conference to Discuss Partnership Initiatives with Leading Biotechnology Companies

Advanced Proteome Therapeutics Corporation ("APC" or the "Company") (TSX VENTURE: APC) (FRANKFURT: 0E8) a biotechnology company focused on developing superior targeted protein therapeutics, will be attending the 2017 BIO-Europe 2017 Conference from...

Sep 07, 2017 08:00 am ET

Advanced Proteome Therapeutics Announces Non-Brokered Private Placement

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATESAdvanced Proteome Therapeutics Corporation ("APC" or the "Company") (TSX VENTURE: APC) (FRANKFURT: 0E8) is pleased to announce that, subject to the approval of...

Jul 31, 2017 08:00 am ET

Advanced Proteome Therapeutics Announces 2017 AGM Results and Corporate Update

Advanced Proteome Therapeutics Corporation ("APC" or the "Company") (TSX VENTURE: APC) (FRANKFURT: 0E8) a biotechnology company focused on developing superior targeted protein therapeutics, today announced the election of its board of directors from...

Jul 18, 2017 08:00 am ET

Advanced Proteome Therapeutics Announces Collaboration to Develop Cancer Therapeutic

Advanced Proteome Therapeutics Corporation ("APC" or the "Company") (TSX VENTURE: APC) (FRANKFURT: 0E8) a biotechnology company focused on developing superior targeted protein therapeutics is pleased to announce a collaboration with the National...

Jul 11, 2017 10:51 am ET

Advanced Proteome Therapeutics Corporation Completes Rights Offering for Gross Proceeds of Approximately $430,000

Advanced Proteome Therapeutics Corporation ("APC" or the "Company") (TSX VENTURE:APC)(FRANKFURT:0E8) is pleased to report that it has completed its previously announced rights offering (the "Rights Offering"). Under the...

Jul 11, 2017 10:51 am ET

Advanced Proteome Therapeutics Corporation Completes Rights Offering for Gross Proceeds of Approximately $430,000

Advanced Proteome Therapeutics Corporation ("APC" or the "Company") (TSX VENTURE: APC)(FRANKFURT: 0E8) is pleased to report that it has completed its previously announced rights offering (the "Rights Offering").

Jun 01, 2017 08:30 am ET

Advanced Proteome Therapeutics Corporation Announces Rights Offering

Advanced Proteome Therapeutics Corporation ("APC" or the "Company") (TSX VENTURE: APC)(FRANKFURT: 0E8) is pleased to announce that it will conduct a rights offering to raise gross proceeds of up to $1,900,281 (the "Rights Offering").

Jun 01, 2017 08:28 am ET

Advanced Proteome Therapeutics Corporation Announces Rights Offering

Advanced Proteome Therapeutics Corporation ("APC" or the "Company") (TSX VENTURE:APC)(FRANKFURT:0E8) is pleased to announce that it will conduct a rights offering to raise gross proceeds of up to $1,900,281 (the "Rights Offering")....

May 18, 2017 08:00 am ET

Advanced Proteome Therapeutics Advances Collaborations

Advanced Proteome Therapeutics Corporation (APC) (TSX VENTURE: APC) (FRANKFURT: 0E8), a biotechnology company focused on producing technologies to perfect the use of antibody drug conjugates for the treatment of various cancers is pleased to...

May 03, 2017 08:00 am ET

Advanced Proteome Therapeutics Corporation Announces Launch of New Corporate Website

Advanced Proteome Therapeutics Corporation ("APC" or the "Company") (TSX VENTURE: APC) (FRANKFURT: 0E8), a biotechnology company focused on producing technologies to perfect the use of antibody drug conjugates for the treatment of various cancers,...

May 01, 2017 11:16 am ET

Advanced Proteome Therapeutics Moves Into Johnson & Johnson Innovation, JLABS @ Toronto

Apr 10, 2017 02:30 pm ET

Advanced Proteome Therapeutics Corporation Announces Bridge Loan Financing

Apr 10, 2017 02:30 pm ET

Advanced Proteome Therapeutics Corporation Announces Bridge Loan Financing

Advanced Proteome Therapeutics Corporation ("APC" or the "Company") (TSX VENTURE: APC)(FRANKFURT: 0E8) announces that it has entered into loan agreements with three lenders for loans in the aggregate amount of $250,000 (the "Loans"). The Loans bear interest at an annual rate of 12% and will be repayable in full on April 7, 2018. In addition, the Company may prepay all or a portion of the Loans in advance at any time without penalty.

Feb 06, 2017 09:00 am ET

Advanced Proteome Therapeutics Corporation Announces the Appointment of Dr. Randal Chase to Its Executive Leadership Team and the Grant of Stock Options

Advanced Proteome Therapeutics Corporation ("APC" or the "Company") (TSX VENTURE: APC) (FRANKFURT: 0E8) is pleased to announce the appointment of Dr. Randal Chase to its executive leadership team to help shape the Company's future and advance its...

Jan 17, 2017 09:00 am ET

Advanced Proteome Therapeutics Corporation Announces Issuance of U.S. Patent Covering Novel Molecules for the Treatment of Cancer

Advanced Proteome Therapeutics Corporation ("APC" or the "Company") (TSX VENTURE: APC) (FRANKFURT: 0E8) is pleased to announce issuance of APC's U.S. Patent Application 14/400,190 titled "Site-Specific Labeling and Targeted Delivery of Proteins for...

Nov 29, 2016 09:00 am ET

APC Invents Quantitative Method for Assessing Pattern of Antibody Labeling Impacting the Emerging, Rapidly Growing Market for Antibody-Drug Conjugates (ADC)

Advanced Proteome Therapeutics Corporation ("APC" or the "Company") (TSX VENTURE: APC) (FRANKFURT: 0E8) is pleased to announce that it has invented a measurable basis for evaluating antibody labeling that provides key information on the pattern of...

Oct 19, 2016 08:00 am ET

Advanced Proteome Therapeutics Corporation Obtains Option to License Antibody Candidates and Collaborates With CCAB to Jointly Fund Research

Advanced Proteome Therapeutics Corporation (APC) (TSX VENTURE: APC) (FRANKFURT: 0E8), a biopharmaceutical company dedicated to creating, developing, and commercializing innovative therapies, today announced that it has entered into an exclusive...

Oct 07, 2016 05:14 pm ET

Advanced Proteome Therapeutics Retains Virtus Advisory Group to Provide Corporate Communication Services

Advanced Proteome Therapeutics Corporation ("APC" or the "Company") (TSX VENTURE: APC) (FRANKFURT: 0E8) is pleased to announce that it has retained Virtus Advisory Group Inc. ("Virtus"), to develop and implement a strategic corporate communications...

Jul 18, 2016 09:00 am ET

Advanced Proteome Therapeutics Corporation Formulates Strategic Plan Featuring Novel Antibody Program

Advanced Proteome Therapeutics Corporation ("APC" or the "Company") (TSX VENTURE: APC) (FRANKFURT: 0E8) announces plans bearing on its site-specific protein modification technology as it applies to therapeutic antibodies. The high demand for...

Jun 14, 2016 09:00 am ET

Advanced Proteome Therapeutics Corporation and Wilex Subsidiary Heidelberg Pharma Collaborate to Create Improved Cancer Therapeutics

WILEX AG (ISIN DE000A11QVV0 / WL6 / FSE) and Advanced Proteome Therapeutics Corporation, Vancouver, Canada (TSX VENTURE: APC) (FRANKFURT: 0E8) today announced that Heidelberg Pharma GmbH, Ladenburg, Germany, a subsidiary of Wilex AG, entered into a...

May 19, 2016 06:26 pm ET

Ad blocking detected

Advanced Proteome Therapeutics Corporation (V:APC)

Business Focus: Shell Companies